Status:
COMPLETED
A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T
Lead Sponsor:
GenesisCare USA
Collaborating Sponsors:
Dendreon
Conditions:
Castrate Refractory Metastatic Prostate Cancer (mCRPC)
Eligibility:
MALE
18+ years
Brief Summary
Radiation in combination with Provenge based immunotherapy may improve outcomes seen on imaging as well as immunologic monitoring. This study will assess the effect of radiation therapy to augment ant...
Detailed Description
It is common knowledge that the host can make anti-tumor immune responses, although often these are ineffective in causing tumor regression. Boosting these responses with immunotherapy is therefore an...
Eligibility Criteria
Inclusion
- Subjects will be recruited from the population of patients who are castrate refractory metastatic prostate cancer (mCRPC) and have made the decision to be treated with radiation therapy to one or more metastatic sites of concern followed at least 28 days later by Provenge.
Exclusion
- The potential subject is unwilling or hesitant to participate for any reason and/or fails to complete the appropriate Informed Consent Form.
Key Trial Info
Start Date :
June 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 5 2018
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02232230
Start Date
June 1 2014
End Date
June 5 2018
Last Update
January 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
21st Century Oncology
Scottsdale, Arizona, United States, 85251